Registered number
10468841
Wiltshire Pharma Ltd
Filleted Accounts
31 March 2024
Wiltshire Pharma Ltd
Registered number: 10468841
Balance Sheet
as at 31 March 2024
Notes 2024 2023
£ £
Current assets
Debtors 4 38,076 21,422
Cash at bank and in hand 120,950 127,899
159,026 149,321
Creditors: amounts falling due within one year 5 (57,868) (46,202)
Net current assets 101,158 103,119
Net assets 101,158 103,119
Capital and reserves
Called up share capital 10 10
Profit and loss account 101,148 103,109
Shareholders' funds 101,158 103,119
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Dr L Cook
Director
Approved by the board on 21 November 2024
Wiltshire Pharma Ltd
Notes to the Accounts
for the year ended 31 March 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery 100% straight line
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2023 625
At 31 March 2024 625
Depreciation
At 1 April 2023 625
At 31 March 2024 625
Net book value
At 31 March 2024 -
4 Debtors 2024 2023
£ £
Trade debtors 38,076 21,422
5 Creditors: amounts falling due within one year 2024 2023
£ £
Taxation and social security costs 57,723 45,783
Other creditors 145 419
57,868 46,202
6 Other information
Wiltshire Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
Tavewa Pye Lane
Broad Town
Swindon
Wiltshire
SN4 7RR
Wiltshire Pharma Ltd 10468841 false 2023-04-01 2024-03-31 2024-03-31 VT Final Accounts July 2024 Dr L Cook No description of principal activity 10468841 2022-04-01 2023-03-31 10468841 core:WithinOneYear 2023-03-31 10468841 core:ShareCapital 2023-03-31 10468841 core:RetainedEarningsAccumulatedLosses 2023-03-31 10468841 2023-04-01 2024-03-31 10468841 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 10468841 bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 10468841 bus:Director40 2023-04-01 2024-03-31 10468841 1 2023-04-01 2024-03-31 10468841 2 2023-04-01 2024-03-31 10468841 countries:England 2023-04-01 2024-03-31 10468841 bus:FRS102 2023-04-01 2024-03-31 10468841 bus:FilletedAccounts 2023-04-01 2024-03-31 10468841 2024-03-31 10468841 core:WithinOneYear 2024-03-31 10468841 core:ShareCapital 2024-03-31 10468841 core:RetainedEarningsAccumulatedLosses 2024-03-31 10468841 core:PlantMachinery 2024-03-31 10468841 2023-03-31 10468841 core:PlantMachinery 2023-03-31 iso4217:GBP xbrli:pure